Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML
Matteo Marchesini(The University of Texas MD Anderson Cancer Center), Giovanni Roti(University of Parma)
Cited by 5
Related Papers
Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma
|Nature Communications|2019|60
The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies
|Cancer Discovery|2020|26
Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma
|RePEc: Research Papers in Economics|2019|11
CAD204520 Targets NOTCH1 PEST Domain Mutations in Lymphoproliferative Disorders
|International Journal of Molecular Sciences|2024|5